Leptomycin Analog Structural Modification for Reduced Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining leptomycin compounds as anti-cancer agents face challenges such as limited structural diversity, low bioconversion yields, and high cytotoxicity, making them unsuitable for effective cancer treatment.
Innovation Solution
Development of novel compounds with specific structural modifications, including varying alkyl, alkenyl, and aryl groups, and the incorporation of fluorescent moieties, which inhibit CRM1-mediated nuclear export, thereby targeting cancer cells and inducing apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If leptomycin B is used as an anti-cancer agent, then it exhibits strong antiproliferative activity by inhibiting CRM1-mediated nuclear export, but it shows remarkable cytotoxicity towards mammalian cells
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of leptomycin B through substitution at specific positions (R1, R2, R3, R4, R5, R6 groups) to create analogs with reduced cytotoxicity while preserving CRM1 inhibition activity. This involves changing physical and chemical parameters of the molecule to optimize its therapeutic profile.
Solution Approach 2:
The patent applies local quality by making specific localized modifications to different regions of the leptomycin B molecule. Each substituent position (R1-R6) represents a local region that can be independently modified to achieve desired properties, allowing optimization of specific aspects of the molecule's behavior without affecting the entire structure.
2Adaptability or versatility
If bioconversion screening with bacteria and fungi is used to obtain leptomycin derivatives, then some derivatives are isolated, but the structural diversity is poor and bioconversion yields are low
Solution Approach 1:
The patent applies parameter changes by using chemical synthesis methods with controlled variables (reagents, conditions, catalysts) to generate diverse leptomycin analogs systematically. This approach provides better control over structural parameters compared to bioconversion, enabling broader structural diversity and higher productivity through methodical exploration of chemical space.
3Manufacturing precision
If systematic derivation of structure-activity relationship is desired, then comprehensive structural modifications are needed, but current bioconversion methods introduce functional groups in haphazard positions
Solution Approach 1:
The patent applies local quality by enabling independent modification of specific positions (R1-R6) in the leptomycin structure through targeted chemical synthesis methods. This allows systematic exploration of structure-activity relationships by controlling which local region is modified and with what substituent, providing precision that bioconversion cannot achieve.
Solution Approach 2:
The patent applies segmentation by treating the leptomycin molecule as a modular structure where different substituent positions (R1-R6) can be independently modified. This segmentation allows systematic derivation of structure-activity relationships by varying one region at a time while keeping others constant, facilitating precise control over structural modifications.
Data Source
AI summary
Leptomycin-type compounds according to Formula Iwherein R0, R1, R2, R10, R11, R12, R13, R14, and m are as defined herein, exhibit anti-tumor activity.